CLAIMS

What is claimed is:

1. A kit for ~~expressing an exogenous sequence~~increasing expression of a transgene encoding a polypeptide product in T cells, the kit comprising at least a first and second co-stimulatory agents, wherein the co-stimulatory agents are provided on one or more beads and further wherein the first co-stimulatory agent comprises a CD3 ligand; and an adenoviral vector comprising (i) a sequence encoding said ~~exogenous sequence~~transgene operably linked to a promoter and (ii) a sequence encoding at least one zinc finger nuclease.

2. The kit according to ~~claim~~ 1, wherein the T cell is a CD4+ cell.

3. The kit according to claim 1, wherein the T cell is a CD8+ cell.

4. The kit according to any one of the preceding claims, wherein ~~at least one of~~ the second co-stimulatory agents comprises an anti-CD3 antibody and/or the CD3 ligand of the first co-stimulatory agent is an anti-CD3 antibody.

5. The kit according to claim 41, wherein the second co-stimulatory agent comprises an anti-CD28 antibody.

6. The kit according to claim 41, wherein the second co-stimulatory agent comprises IL-15.

7. The kit according to claim 41, wherein the second co-stimulatory agent comprises a feeder cell.

8. The kit according to any of claims 1 to 7, wherein the adenoviral vector is pseudotyped.

9. The kit according to claim 8, wherein the pseudotyped adenovirus expression vector comprises (i) sequences from Ad5 and Ad35 adenoviruses.

10. The kit according to claim 9, wherein the Ad35 sequence is F35.

~~11. The kit according to any one of the preceding claims, wherein the adenoviral vector comprises (ii) a sequence encoding at least one zinc finger nuclease.~~

~~12.~~11. A pharmaceutical composition comprising at least first and second co-stimulatory agents, wherein the co-stimulatory agents are provided on one or more beads and further wherein the first co-stimulatory agent comprises a CD3 ligand; and an adenovirus vector comprising (i) ~~said exogenous~~a sequence encoding a transgene operably linked to a promoter and (ii) a sequence encoding at least one zinc finger nuclease.

~~13. A pharmaceutical composition comprising:~~

~~T-cells obtained by activation and transduction of T-cells with a pharmaceutical composition according to claim 12 and~~

~~a pharmaceutically acceptable carrier.~~